Loading...
China Resources Medical Holdings Company Limited
1515.HK•HKSE
Healthcare
Medical - Care Facilities
HK$3.68
HK$-0.10(-2.65%)

Financial performance has remained strong, with revenue growing from $4.70B in Q4 2022 to $4.98B in Q2 2024. Gross profit continued to perform well, with margins at 21% in the latest quarter. Operating income reached $562.68M in Q2 2024, holding a steady 11% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $840.13M. Net income rose to $433.95M, keeping EPS at $0.34. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan